Shanghai Youcardi Intelligent Life Technology Co., Ltd

The main purpose of the Phase I study is to evaluate the safety and tolerability of U16 in the treatment of refractory and relapsed B-cell Non-Hodgkin's Lymphoma (r/r B-NHL) and confirm the recommended dose (RP2D) for Phase II. Secondary study objectives: 1. Preliminary evaluation of the effectiveness of U16 in the treatment of r/r B-NHL; 2. Evaluate the pharmacokinetic (PK) characteristics of U16 in the treatment of r/r B-NHL; 3. Evaluate the pharmacodynamic (PD) characteristics of U16 injection in the treatment of r/r B-NHL. The main purpose of the Phase II study is to evaluate the effectiveness of U16 in the treatment of refractory and relapsed B-cell Non-Hodgkin's Lymphoma (r/r B-NHL). Secondary study objectives: 1. Further evaluate the effectiveness of U16 in the treatment of r/r B-NHL; 2. Evaluate the safety and tolerability of U16 in the treatment of r/r B-NHL; 3. 1. To evaluate the pharmacokinetic (PK) characteristics of U16 in the treatment of r/r B-NHL; 2. To evaluate the pharmacodynamic (PD) characteristics of U16 in the treatment of r/r B-NHL.